PregLem's Esmya positive in Phase III for uterine fibroids
This article was originally published in Scrip
PregLem's lead product, the oral progesterone receptor modulator Esmya (ulipristal acetate), has met the primary endpoint in a Phase III non-inferiority study (PEARL II) comparing it with leuprorelin for the treatment of symptomatic uterine fibroids (myoma). Leuprorelin, a gonadotropin-releasing hormone agonist, is the only pharmaceutical treatment currently approved for the condition and is delivered via monthly subcutaneous injection.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.